3-(thiophen-3-yl)propan-1-amine | 119451-18-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(thiophen-3-yl)propan-1-amine
• 英文别名: 3-thiophen-3-ylpropan-1-amine
• CAS: 119451-18-2
• 化学式: C₇H₁₁NS
• mdl: MFCD09912909
• 分子量: 141.237
• InChiKey: BAKKNRUWGAAXIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  BOC-D-丙氨酸 、 3-(thiophen-3-yl)propan-1-amine 生成 tert-butyl N-[(2R)-1-oxo-1-(3-thiophen-3-ylpropylamino)propan-2-yl]carbamate
  参考文献：
  名称：

  HANSEN, DONALD W. (JR);PITZELE, BARNETT S.;HAMILTON, ROBERT W.;CLARE, MIC+

  摘要：

  DOI：

文献信息

• Bicyclic cyclohexylamines and their use as nmda receptor antagonists
  申请人：——

  公开号：US20030236252A1

  公开（公告）日：2003-12-25

  Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification. 1

  描述了公式（I）的自行车替代环己胺及其药用盐。这些化合物是NMDA受体通道复合物的拮抗剂，可用于治疗脑血管疾病，例如脑缺血、心脏骤停、中风和帕金森病。这些取代基在规范中有定义。
• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] INHIBITEURS D'EZH2 (ENHANCER OF ZESTE HOMOLOG 2)
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016066697A1

  公开（公告）日：2016-05-06

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homo log 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是Enhancer of Zeste Homo log 2 (EZH2)的抑制剂，包括含有它们的药物组合物，它们的制备方法，以及它们在治疗癌症中的应用。
• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] AMPLIFICATEUR DES INHIBITEURS DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017002064A1

  公开（公告）日：2017-01-05

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是增强子Zeste同源物2（EZH2）的抑制剂，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗癌症方面的用途。
• [EN] NEW PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS<br/>[FR] NOUVEAUX DÉRIVÉS DE PROPANAMINE PERMETTANT DE TRAITER LA DOULEUR ET DES ÉTATS PATHOLOGIQUES ASSOCIÉS À LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2019020792A1

  公开（公告）日：2019-01-31

  The present invention relates to new compounds of general formula (I) that show dual activity towards α2δ subunit of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit, and to the noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

  本发明涉及一般式(I)的新化合物，该化合物对电压门控钙通道（VGCC）的α2δ亚基，特别是α2δ-1亚基，以及去甲肾上腺素转运蛋白（NET）显示双重活性。该发明还涉及制备所述化合物的方法，以及包含它们的组合物，并将其用作药物。
• Queuine Analogues Incorporating the 7‐Aminomethyl‐7‐deazaguanine Core: Structure–Activity Relationships in the Treatment of Experimental Autoimmune Encephalomyelitis
  作者：Michelle Cotter、Sreeja Varghese、Franciane Chevot、Claire Fergus、Vincent P. Kelly、Stephen J. Connon、J. Mike Southern

  DOI：10.1002/cmdc.202300207

  日期：2023.9

  A library of queuine analogues targeting the modification of tRNA isoacceptors for Asp, Asn, His and Tyr catalysed by queuine tRNA ribosyltransferase (QTRT, also known as TGT) was evaluated in the treatment of a chronic multiple sclerosis model: murine experimental autoimmune encephalomyelitis. Several active 7‐deazaguanines emerged, together with a structure–activity relationship involving the necessity for a flexible alkyl chain of fixed length.

  摘要 针对奎宁 tRNA 核糖转移酶（QTRT，又称 TGT）催化的 tRNA 对 Asp、Asn、His 和 Tyr 的异接受体的修饰，我们评估了一个奎宁类似物库，用于治疗慢性多发性硬化症模型：小鼠实验性自身免疫性脑脊髓炎。结果发现了几种具有活性的 7-脱氮鸟嘌呤，同时还发现了一种结构-活性关系，即必须有固定长度的柔性烷基链。